BACKGROUND: There is increasing evidence that primary tumor ablation can improve survival for some cancer patients with distant metastases. This may be particularly applicable to head and neck squamous cell carcinoma (HNSCC) because of its tropism for locoregional progression. METHODS: This study included patients with metastatic HNSCC undergoing systemic therapy identified in the National Cancer Data Base. High-intensity local treatment was defined as radiation doses 60 Gy or oncologic resection of the primary tumor. Multivariate Cox regression, propensity score matching, landmark analysis, and subgroup analysis were performed to account for imbalances in covariates, including adjustments for the number and location of metastatic sites in the subset of patients with this information available. RESULTS: In all, 3269 patients were included (median follow-up, 51.5 months). Patients undergoing systemic therapy with local treatment had improved survival in comparison with patients receiving systemic therapy alone in propensity score-matched cohorts (2-year overall survival, 34.2% vs 20.6%; P < .001). Improved survival was associated only with patients receiving high-intensity local treatment, whereas those receiving lower-intensity local treatment had survival similar to that of patients receiving systemic therapy without local treatment. The impact of high-intensity local therapy was time-dependent, with a stronger impact within the first 6 months after the diagnosis (adjusted hazard ratio [AHR], 0.255; 95% confidence interval [CI], 0.210-0.309; P < .001) in comparison with more than 6 months after the diagnosis (AHR, 0.622; 95% CI, 0.561-0.689; P < .001) in the multivariate analysis. A benefit was seen in all subgroups, in landmark analyses of 1-, 2-, and 3-year survivors, and when adjusting for the number and location of metastatic sites. CONCLUSIONS: Aggressive local treatment warrants prospective evaluation for select patients with metastatic HNSCC. Cancer 2017;123:4583-93.
INTRODUCTION
In the vast majority of cancers, the development of distant metastasis (DM) heralds an incurable disease state. However, there is emerging evidence from both randomized trials and retrospective studies showing that with some malignancies, locoregional treatment for patients with DM undergoing systemic therapy may improve outcomes in comparison with systemic therapy alone. [1] [2] [3] [4] [5] [6] [7] Although the prevention of morbidity and mortality due to locoregional progression may drive a significant proportion of this benefit, local disease eradication may also hypothetically reduce the overall subclone burden, disrupt the seeding of cells from the local tumor, 8 reduce tumor-produced growth factors and cytokines, 9, 10 and alter the immune micro-environmental landscape. 11 The concept of local disease eradication in patients with systemic dissemination may be particularly applicable to head and neck squamous cell carcinoma (HNSCC). Locoregional control is of paramount importance in HNSCC both because of the unique tropism of HNSCC for locoregional progression 12 and because organs in this anatomic region control critical fundamental human functions, including breathing, swallowing, speaking, and cranial nerve function. As a result, the primary source of morbidity and mortality in HNSCC is often locoregional progression, even for those presenting with DM.
Consideration of locoregional treatment for patients presenting with DM is recommended by National Comprehensive Cancer Network guidelines. However, there are limited data examining the role of aggressive locoregional therapy, including oncologic surgery or curativedose radiation, versus less aggressive or no local therapy in these patients. We hypothesized that aggressive treatment of the primary tumor site would be associated with improved survival for patients with metastatic HNSCC receiving chemotherapy. Using a large cohort of patients presenting with DM from the National Cancer Data Base (NCDB), we compared overall survival (OS) for patients receiving systemic therapy alone or in combination with high-or low-intensity local therapy.
MATERIALS AND METHODS

Database Information
This study used de-identified patient data from the NCDB for patients diagnosed between 2004 and 2012. The NCDB is a hospital-based cancer registry maintained by both the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The NCDB includes patients from more than 1500 accredited facilities, which represent approximately 70% of cancers diagnosed in the United States. The Commission on Cancer's NCDB and the hospitals participating in the NCDB are the source of the deidentified data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by us. This study was deemed to be exempt from full Institutional Review Board review by Cedars-Sinai Medical Center.
Treatment Information
The primary purpose of this study was to determine whether high-intensity local therapy, similar to what would be delivered in the curative setting, was associated with improved survival for patients with metastatic HNSCC receiving systemic therapy. Because 60 Gy is the lowest dose that generally would be used for HNSCC patients undergoing curative treatment, high-intensity local therapy was defined as 1) the receipt of a cumulative radiation dose to the head and neck 60 Gy, 2) oncologic surgery to the primary site, such as pharyngectomy, subtotal or total laryngectomy, or partial, hemi-, or total glossectomy, or 3) both. Lower intensity local therapy was defined as radiation to the head and neck at doses < 60 Gy or more limited surgical procedures, such as local tumor destruction (surgery codes 10-15), local tumor excision, biopsy, cryosurgery, electrocautery, photodynamic therapy, or laser ablation (surgery codes [20] [21] [22] [23] [24] [25] [26] [27] [28] , unless head and neck radiotherapy to doses 60 Gy was also delivered.
Patient Selection
This study included patients with invasive squamous cell carcinoma of the nasopharynx, oropharynx, oral cavity, larynx, or hypopharynx who presented with DM diagnosed between 2004 and 2012 and underwent systemic therapy (Supporting Fig. 1 [see online supporting information]). Patients whose follow-up details were unknown (n 5 1182), whose histology was nonsquamous (n 5 1021), who were not receiving chemotherapy (n 5 2634), or for whom details regarding the receipt of either chemotherapy (n 5 232) or radiation (n 5 242) were unknown were excluded. Patients with ambiguous surgery codes (n 5 318) or unknown radiation doses (n 5 37), such that it could not be determined whether high-intensity local therapy had been delivered, were also excluded. In addition, patients with unknown values for covariates included in our multivariate models were excluded (n 5 1097).
In total, 3269 patients met the inclusion criteria of this study. A subgroup analysis accounting for the number and location of organs with metastases was performed for 1059 patients with the confirmed presence or absence of lung, liver, bone, and brain metastases. High-volume facilities were defined as the top 2.5% of facilities by treatment volume.
Statistical Analysis
Baseline characteristics were compared with a 1-way analysis of variance for continuous covariates and with chisquare tests for categorical covariates. Predictors of the receipt of high-intensity local therapy were identified with logistic regression. The Kaplan-Meier method was used to estimate OS, and survival curves were compared with the log-rank test. A Cox proportional hazards model was used for univariate and multivariate analyses. Proportional hazards assumptions were tested with scaled Schoenfeld residuals. Because high-intensity local treatment violated the proportional hazards assumption, a Cox regression with time-varying coefficients for high-intensity local treatment was used. We dichotomized the effect of this variable into 6 months and >6 months from the diagnosis on the basis of the inflection point of the change in effect from the plot of the scaled Schoenfeld residual for highintensity local treatment (data not shown). High-intensity local treatment was then entered into our model as an interaction with time 6 months and > 6 months from diagnosis. Multicollinearity was assessed by tolerance and the variance inflation factor. Propensity scores were calculated via the fitting of a logistic regression model and were matched by the nearest neighbor method. To account for an immortal-time bias, we performed a landmark analysis of 1-, 2-, and 3-year survivors. 13 For subgroup analyses testing the impact of high-intensity local therapy on OS among various subgroups, a Bonferroni correction for multiple-hypothesis testing was applied (P 5 .05/14 5 0.004). All statistical analyses were performed with the R package (version 3.3.2) with 2-sided tests and a significance level of .05.
RESULTS
In total, 1495 (45.7%), 650 (19.9%), and 1124 patients (34.4%) received high-intensity, low-intensity, and no local treatment, respectively (Table 1) . Of those receiving high-intensity local treatment, 1299 received radiation, 121 received surgery, and 75 received both. All patients received systemic therapy. With multivariate logistic regression (Supporting Table 1 [see online supporting information]), female sex, stage N3, treatment at an academic center, multi-agent systemic therapy, and higher comorbidity were associated with lower utilization of high-intensity local therapy. In contrast, private insurance and residential education level were associated with significantly more frequent use of high-intensity local therapy.
The median follow-up for surviving patients was 51.5 months. In propensity score-matched cohorts (Supporting Table 2 [see online supporting information]), OS was significantly longer for those receiving combined local therapy and systemic therapy in comparison with patients receiving systemic therapy alone (2 year OS, 34.2% vs 20.6%; P < .001; Fig. 1A ). When we stratified patients receiving local therapy into high-intensity and lowintensity subgroups, only high-intensity local treatment was associated with significantly prolonged OS in comparison with no local treatment in univariate and multivariate analysis ( Table 2 and Fig. 1B ). There was no difference in OS for patients receiving low-intensity local therapy and patients receiving no local therapy. The 2-year OS rates were 40.5%, 19.8%, and 20.6% for patients receiving high-intensity, low-intensity, and no local treatment, respectively (P < .001). Similar results were observed in landmark analyses restricted to patients surviving 1, 2, and 3 years after their diagnosis, respectively ( Fig. 2A-C) .
Because the effect of high-intensity local treatment on survival was found to vary over time and violate the proportional hazards assumption, the effect of this variable was estimated separately within 6 months of the diagnosis and more than 6 months after the diagnosis (Table  2) . Significantly improved OS was observed with Abbreviations: CI, confidence interval; HR, hazard ratio. Because the primary variable of interest, high-intensity local treatment, was found to violate the proportional hazards assumption, this variable was dichotomized into its effect during the first 6 months after diagnosis and its effect more than 6 months after diagnosis. a Dropped from the multivariate model.
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combined systemic therapy and high-intensity local therapy in comparison with systemic therapy alone during both follow-up periods in multivariate analyses, although the effect was greater within the first 6 months of treatment (adjusted hazard ratio [AHR] for 6 months, 0.255; 95% confidence interval [CI], 0.210-0.309; P < Figure 2 . Landmark analysis of (A) 1-year survivors, (B) 2-year survivors, and (C) 3-year survivors among patients with metastatic head and neck squamous cell carcinoma receiving systemic therapy in combination with high-intensity local treatment, lower intensity local treatment, or no local treatment.
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Cancer .001; AHR for >6 months, 0.622; 95% CI, 0.561-0.689; P < .001). In subgroup analysis, high-intensity local therapy was associated with improved OS across all subgroups when adjustments were made for other covariates (Fig. 3) . There was no significant interaction between the benefit of high-intensity local therapy and any investigated covariate when applying the Bonferroni correction to adjust for multiple hypothesis testing. Because the overall burden of systemic disease at presentation could vary between patients, a subgroup analysis of the 1059 patients with documentation for the presence or absence of lung, liver, bone, and brain metastasis was performed. As in the full cohort, improved survival was seen with combined systemic therapy and highintensity local therapy (but not lower intensity local therapy) in comparison with systemic therapy alone (Supporting Fig. 2A [see online supporting information]). Patients undergoing high-intensity local therapy had improved survival in comparison with other patients in propensity score-matched cohorts when the number and location of metastatic anatomic sites were included in the propensity score (2-year OS, 39.6% vs 18.4%; P < .001; Fig. 4 and Supporting Table 3 [see online supporting information]). Similarly, systemic treatment with high-intensity local therapy was independently associated with improved survival in comparison with systemic therapy alone (AHR for 6 months, 0.329; 95% CI, 0.236-0.459; P < .001; AHR for >6 months, 0.595; 95% CI, 0.490-0.723; P < .001), whereas there was no difference in survival with lower intensity local therapy (hazard ratio, 1.100; 95% CI, 0.907-1.334; P 5 .333) when adjustments were made for the number and location of metastatic anatomic sites in multivariate models (Supporting Table 4 [see online supporting information]). Notably, the presence of 3 to 4 metastatic sites (hazard ratio, 3.429; 95% CI, 2.156-5.454; P < .001) and 2 metastatic sites (hazard ratio, 1.801; 95% CI, 1.442-2.249; P < .001) were independently associated with worse survival in comparison with a single metastatic site. Improved survival with high-intensity local therapy was observed both for the subgroup of patients with a single anatomic site involved with metastasis and for patients with multiple sites of metastases in the multivariate analysis (interaction P 5 .107; Supporting 
DISCUSSION
In this study, we found that HNSCC patients presenting with DM and receiving systemic therapy experienced improved OS if treatment was delivered to the primary tumor site. This effect was entirely associated with highintensity local treatment, such as radiotherapy delivered at curative doses or oncologic surgical procedures. In contrast, no difference in survival was observed in patients undergoing systemic therapy with or without lower intensity local treatment. The benefit of high-intensity local therapy was consistently observed across virtually all subgroups and when we controlled for the number of sites harboring DM with multivariate regression and propensity score-matched cohorts. Notably, although a significant survival benefit from high-intensity local therapy was observed at all time points during this study, the magnitude of the effect varied over time, with a greater benefit found within 6 months of the diagnosis. This is likely due in part to the fact that virtually all patients in this cohort eventually experienced systemic progression. In addition, both immortal-time bias, whereby patients needed to survive long enough to complete high-intensity local treatment, and selection bias, whereby patients having good responses to systemic therapy were more likely to receive high-intensity local therapy, could have contributed to the larger effect size observed for high-intensity local therapy during the first 6 months. To address this, we performed landmark analyses of 1-, 2-, and 3-year survivors, and we continued to observe significantly improved survival with high-intensity local therapy in all groups. Thus, we believe that these data support a benefit of highintensity local treatment for metastatic head and neck cancer, but we favor using the 38% relative decrease in mortality observed beyond 6 months of follow-up as a conservative estimate of its magnitude because of the greater potential for bias at earlier time points.
Although several previous studies of local treatment for metastatic HNSCC have been reported, [14] [15] [16] our study design contains several key distinctions. It is the first to distinguish ablative high-intensity treatment from lower intensity local treatment while uniformly requiring all patients to receive systemic therapy. In addition, we used a rigorous statistical methodology, including landmark analysis, time-dependent coefficients, and propensity score matching, to counter selection biases inherent to observational studies where treatments are not randomized. Lastly, ours is the only study to account for the extent of systemic involvement.
Although our results suggest a benefit from combined systemic therapy and high-intensity local therapy across a wide range of patients, proper patient selection is critical. It is unlikely that all HNSCC patients with DM will benefit from aggressive locoregional therapy, and the toxicity of treatment to this region can be substantial. Intuitively, those with a high locoregional-to-distant disease burden ratio will derive the greatest benefit. Patientassociated factors, such as performance status and comorbidity burden, may help to identify those with the greatest likelihood of tolerating aggressive therapy. For patients with a substantial systemic disease burden, a poor performance status, or a limited life expectancy, less aggressive local treatment may be appropriate to prevent symptomatic progression that may result in pain, dysphagia, airway obstruction, bleeding, weight loss, and foul-smelling ulcerations. Hypofractionated palliative radiation regimens can have objective response rates of 50% to 80% and may be appropriate for patients with metastatic HNSCC who are not good candidates for high-intensity local therapy. 17, 18 Because of the complexity of the riskbenefit equation for patients who present with DM, it is imperative to discuss goals of care and understand patient preferences to facilitate informed decision making.
There are several explanations for a beneficial effect from locoregional treatment for patients with head and neck cancers who present with DM. Perhaps the simplest explanation is that, because this region contains structures that facilitate breathing, eating, and speaking in addition to blood vessels and nerves necessary for survival, locoregional progression represents the most imminent source of mortality for many patients with metastatic HNSCC. In addition, alternative factors may be important. For example, the ablation of locoregional cancer cells may disrupt this multidirectional tumor spread, 8, [19] [20] [21] statistically decrease the spectrum of cell-to-cell heterogeneity, and promote beneficial micro-environmental changes by enhancing antitumor immunity or eliminating soluble cytokines and growth factors secreted by the tumor.
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The delivery of high-intensity local treatment for metastatic head and neck cancer was statistically more common at nonacademic centers. However, it should be noted that this practice was relatively common in all treatment settings. For example, high-intensity local treatment was delivered to 42% and 48% of patients treated at academic and nonacademic centers, respectively, and to 43% and 46% of those treated at high-volume and lower volume facilities, respectively. This widespread utilization of high-intensity local treatment without strong clinical evidence highlights the importance of investigating the role of this treatment strategy in metastatic head and neck cancer.
Several novel therapeutic approaches may help to optimize the risk-benefit ratio of aggressive local treatment for metastatic HNSCC, although prospective validation is necessary. For example, eliminating elective target coverage and treating the gross tumor only for metastatic patients undergoing locoregional radiation, as is standard practice in the re-irradiation setting, 22 may help to minimize toxicity. This approach has been studied in patients with localized disease who respond to induction chemotherapy in the curative setting and does not appear to compromise locoregional control. 23 In situations where elective target coverage is deemed necessary, the radiation dose to macroscopically uninvolved regions could be minimized. 24 The response to chemotherapy may be used to triage patients likely to benefit from aggressive locoregional therapy because those with progressing systemic disease may obtain less benefit from local treatment. Lastly, early involvement of palliative care should be considered for all patients undergoing aggressive local therapy in the setting of DM. 25 Early palliative care intervention not only has been shown to improve the quality of life, decrease psychosocial distress, and reduce the caregiver burden for patients with incurable cancer but also has been demonstrated to improve survival. [26] [27] [28] [29] This study has multiple strengths and limitations. First, this is a retrospective, nonrandomized study with all the potential biases of such investigations. Most significantly, it is possible that patients with more extensive systemic disease were less likely to receive aggressive locoregional treatment. To address this, we performed a subgroup analysis of patients with documented sites of metastatic spread, and we found high-intensity local therapy continued to prolong survival with a similar magnitude when we controlled for the number and location of organs with metastases in propensity score-matched and multivariate analyses. Notably, patients with 2 or 3 anatomic sites with metastases had a 1.8 or 3.4 times greater risk of death, respectively, than those with a single site of metastasis, suggesting that this is a valid approximation for the overall systemic disease burden. To our knowledge, this is the first NCDB study of any metastatic cancer investigating the impact of local treatment to adjust for systemic disease burden. 4, 5, 7 A selection bias based on the chemotherapy response is also possible in an observational study. We accounted for this potential bias in 2 ways. First, we performed a landmark analysis of patients surviving at least 1, 2, and 3 years after the diagnosis, and we found that patients receiving high-intensity local therapy had prolonged survival in all subgroups. Because the median survival for patients with metastatic head and neck cancer is 7 to 10 months, 30 these long-term survivors would all be expected to have had excellent responses to chemotherapy, thereby mitigating the potential for both chemo-selection bias and immortal-time bias. Second, we analyzed the effect of high-intensity local treatment in a time-dependent fashion, because its impact on survival was variable over time and strongest within 6 months of diagnosis, violating the Cox proportional hazards assumption. Because this could be explained in part by patients who progressed early during chemotherapy being less likely to receive local therapy, we advocate estimating the magnitude of the impact of high-intensity local therapy on survival with the time-dependent covariate of beyond 6 months from the diagnosis. The fact that the hazard ratio for high-intensity local therapy beyond 6 months showed no additional variation over time on the basis of Schoenfeld residuals and was nearly identical in both the main analysis and the subgroup analysis adjusting for the number and location of metastatic sites (Table 2 and Supporting Table 4 [see online supporting information]) suggests that this is a relatively stable, conservative estimate of its effect in metastatic head and neck cancer.
Multiple other limitations warrant discussion. Younger, healthier patients were more likely to receive high-intensity local treatment than older patients and those with more significant comorbidities. We adjusted for both age and comorbidity status in all multivariate models, but certain baseline characteristics that could influence survival, such as the performance status, marital status, pretreatment weight loss, and smoking history, are not included in the NCDB and could not be accounted for. The NCDB also lacks information on the specific type and duration of the systemic regimen delivered, although we adjusted for single-agent chemotherapy versus multi-agent chemotherapy in all analyses. We also note that our study includes cancers arising from a variety of head and neck subsites, which are known to have differing biologies and clinical behaviors. 31 Moreover, data about human papillomavirus, which has been correlated with prognosis in recurrent or metastatic oropharyngeal cancers, 32 was not available for the majority of the patients. Nevertheless, all anatomic head and neck subsites share the potential for lethal locoregional progression, and the magnitude of the effect of high-intensity local therapy was similar across all anatomic subsites in the subgroup analysis; this suggests that neither anatomic heterogeneity nor imbalances in the human papillomavirus status are the primary driver of our results. Finally, the NCDB has no information on toxicity or quality of life, which is a critical component of any discussion of the risks and benefits of an intense treatment for patients with an incurable disease.
In conclusion, we believe that despite the limitations of this observational data set, our study provides the clearest information to date regarding the benefit of highintensity local therapy for patients with metastatic HNSCC undergoing systemic therapy. Although optimal patient selection remains uncertain, we observed a benefit across virtually all subgroups of patients. We believe that the role of combined high-intensity local therapy and systemic therapy in HNSCC patients presenting with DM warrants a prospective evaluation, particularly for patients with oligometastatic disease. Accrual for such a trial would be challenging because only approximately 3% of HNSCCs present with DM, 33 and it likely will require international collaboration. Nevertheless, because of the intensity of ablative local treatment in the head and neck combined with the poor outcomes of patients with metastatic HNSCC, it would behoove both patients and physicians to ascertain high-level evidence regarding the benefit of aggressive local therapy for those with DM and to determine for which populations the cost-benefit ratio is optimal. Clinical trials to validate our results represent a critical unmet need in head and neck cancer.
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